Predictive Oncology Inc. (POAI)

Predictive Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	1.78	1.51	1.42	1.25	1.41
Revenue Growth (YoY)	18.24%	5.97%	13.45%	-11.28%	-0.01%
Cost of Revenue	0.63	0.51	0.49	0.45	0.53
Gross Profit	1.15	1	0.93	0.81	0.88
Selling, General & Admin	10.94	12.47	11.71	10.94	11.69
Other Operating Expenses	4.36	14.57	9.9	17.66	15.3
Operating Expenses	15.29	27.04	21.6	28.59	26.99
Operating Income	-14.15	-26.04	-20.67	-27.79	-26.11
Other Expense / Income	-0.17	-0.3	-0.35	-1.9	-6.72
Pretax Income	-13.98	-25.74	-20.32	-25.88	-19.39
Income Tax	0	0	-0.66	0	0
Net Income	-13.98	-25.74	-19.66	-25.88	-19.39
Preferred Dividends	0	0	0	0.55	0.29
Net Income Common	-13.98	-25.74	-19.66	-26.44	-19.68
Shares Outstanding (Basic)	4	4	3	1	0
Shares Outstanding (Diluted)	4	4	3	1	0
Shares Change	8.92%	34.34%	359.21%	316.36%	123.95%
EPS (Basic)	-3.48	-6.98	-7.20	-44.20	-137.20
EPS (Diluted)	-3.48	-6.98	-7.20	-44.20	-137.20
Free Cash Flow	-13.47	-12.79	-13.12	-12.36	-8.74
Free Cash Flow Per Share	-3.35	-3.47	-4.78	-20.69	-60.89
Gross Margin	64.34%	66.45%	65.72%	64.29%	62.32%
Operating Margin	-794.86%	-1729.63%	-1454.81%	-2218.93%	-1849.82%
Profit Margin	-785.58%	-1709.62%	-1383.65%	-2111.26%	-1394.25%
Free Cash Flow Margin	-756.46%	-849.62%	-923.46%	-987.23%	-619.05%
EBITDA	-13.24	-24.42	-18.98	-24.86	-18.69
EBITDA Margin	-744.04%	-1622.40%	-1335.88%	-1985.16%	-1323.77%
Depreciation & Amortization	0.74	1.31	1.34	1.02	0.7
EBIT	-13.98	-25.74	-20.32	-25.88	-19.39
EBIT Margin	-785.58%	-1709.62%	-1430.22%	-2066.99%	-1373.71%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).